Oncology Medical News about transdermal buprenorphine; cancer pain

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus
Current Medical Research and Opinion, 06/22/09

Pergolizzi JV et al. - In an article to provide practical guidance on treatment of cancer pain with transdermal buprenorphine, particularly when there is a need for increasing pain relief leading to high and increasing doses, the consensus was that transdermal buprenorphine has a valuable role to play in treatment of chronic cancer pain because of its efficacy and good safety and tolerability profile, including a low risk of respiratory depression, lack of immunosuppression, and lack of accumulation in pts with impaired renal function.

Methods

A literature search on the use of transdermal buprenorphine was carried out for the panel meeting and a number of case histories were presented and discussed.
This commentary article presents this evidence and the consensus findings of the expert panel.

Results

The Panel reached consensus that transdermal buprenorphine was a valuable treatment for chronic cancer pain, including its neuropathic components.
Large-scale, randomised clinical studies are needed to provide product comparisons on the use of analgesics in the treatment of neuropathic pain although it was recognised that such studies may not be practicable.
Data on treatment of acute and chronic pain should be kept separate in general.
Physicians should be made more aware of the problem of hyperalgesic effects of some opioids in long term use.
Buprenorphine in contrast has been described to exert an antihyperalgesic effect.
Development of analgesic tolerance with some opioids in long-term use and the lack of it with buprenorphine requires further studies.
The registered dose range of 35–140 μg/h was considered adequate to achieve sufficient pain relief in most pts, although some members of the panel presented data showing that increases beyond this dose range provided improved pain relief if slow titration is used.

Exclusive Author Commentary
Joseph V Pergolizzi, 06/18/09

The consensus was that transdermal buprenorphine has a valuable role to play in the treatment of chronic cancer pain because of its efficacy and good safety and tolerability profile, including a low risk of respiratory depression, a lack of immunosuppression and a lack of accumulation in patients with impaired renal function.

<< Previous
Malignant pleural mesothelioma: Computed tomography and...

Next >>
Preoperative evaluation of synchronous colorectal cancer using MR...